A Phase 2 Study of Pemigatinib (FIGHT-203; INCB054828) in Patients with Myeloid/Lymphoid Neoplasms (MLNs) with Fibroblast Growth Factor Receptor 1 (FGFR1) Rearrangement (MLN <i>FGFR1</i>)Jason Gotlib, Srđan Verstovšek, Philomena Colucci et al.|Blood|2021Cited by 51
FIGHT-203, an Ongoing Phase 2 Study of Pemigatinib in Patients With Myeloid/Lymphoid Neoplasms (MLNs) With Fibroblast Growth Factor Receptor 1 (<i>FGFR1</i>) Rearrangement (MLN<i>FGFR1</i>): A Focus on Centrally Reviewed Clinical and Cytogenetic Responses in Previously Treated PatientsSrđan Verstovšek, Jean‐Jacques Kiladjian, Jason Gotlib et al.|Blood|2022Cited by 14
Comprehensive response criteria for myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions: a proposal from the MLN International Working GroupWilliam Shomali, Jason Gotlib, Philomena Colucci et al.|Leukemia|2023Cited by 14
Pemigatinib for Myeloid/Lymphoid Neoplasms with <i>FGFR1</i> RearrangementSrđan Verstovšek, Jason Gotlib, Tracy I. George et al.|NEJM Evidence|2025Cited by 7